Pharma Equity Group A/S Cl A

PEG · CO · Healthcare / Biotechnology

0.0726DKK+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.0726

Open0.0724

Day Range0.0724 – 0.0792

52-Week Range0.0602 – 0.12

Volume323.27K

Market Cap98.20M

P/E (TTM)0.00

Forward P/E0.00

EPS-0.01

Dividend Yield0.00%

Beta1.06

50-Day Avg0.0837

200-Day Avg0.0882

About

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma that are in Phase II clinical trials. The company was incorporated in 2002 and is headquartered in Horsholm, Denmark.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Christian Henrik Tange
Employees5
HeadquartersSlotsmarken 12, 1. th., Horsholm, Denmark, 2970, Denmark
Websitehttps://www.pharmaequitygroup.com

Leadership

Mr. Christian Henrik TangeChief Executive Officer · b. 1966
Mr. Peter EkmanFinancial Manager · b. 1959
Dr. Lars Otto UttenthalChief Medical Officer

Financials

Income Statement

Currency: DKK	2008-09-30	2009-09-30	2010-09-30	2011-09-30	2012-09-30	2013-09-30	2014-09-30	2015-09-30	2016-09-30	2017-09-30	2018-09-30	2019-09-30	2020-09-30	2021-09-30	2022-09-30	2023-09-30	2024-09-30	2025-09-30
Total Revenue	-	-	517.00K	15.49M	13.25M	49.37M	132.00K	620.00K	1.05M	-	-	-	-	0	0	0	0	0
Growth (%)	-	-	-	+2895.36%	-14.43%	+272.52%	-99.73%	+369.70%	+70.00%	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	147.00K	7.10M	6.53M	40.27M	-	-	-	-	-	-	-	-	0	480.00K	235.00K	311.00K
Gross Profit	-	-	370.00K	8.38M	6.72M	-	-	620.00K	1.05M	-	-	-	-	-	0	-480.00K	-235.00K	-311.00K
Gross Margin	-	-	71.57%	54.13%	50.74%	-	-	100.00%	100.00%	-	-	-	-	-	-	-	-	-
Operating Expense	-	-	5.52M	6.89M	6.78M	-	-	3.71M	2.81M	-	-	-	-	-	-3.03M	24.81M	21.05M	24.98M
Operating Income	-103.73M	-980.00K	-5.15M	1.49M	-58.00K	-5.24M	-2.00M	-3.09M	-1.76M	-1.98M	-1.67M	-1.67M	-17.61M	-1.44M	3.03M	-25.29M	-21.29M	-25.29M
Operating Margin	-	-	-996.71%	9.63%	-0.44%	-10.61%	-1517.42%	-498.23%	-166.60%	-	-	-	-	-	-	-	-	-
EBITDA	-92.67M	-924.00K	3.38M	1.49M	-4.75M	-135.32M	-5.99M	-2.63M	-2.02M	177.00K	-7.59M	-14.39M	-32.60M	6.06M	4.47M	-24.80M	-21.04M	-24.98M
EBITDA Margin	-	-	654.55%	9.63%	-35.84%	-274.12%	-4539.39%	-423.71%	-191.18%	-	-	-	-	-	-	-	-	-
Net Income	-92.67M	-12.04M	-1.42M	-16.98M	-43.28M	-141.83M	-5.93M	-2.77M	-1.03M	177.00K	-7.71M	-14.42M	-32.88M	5.39M	3.48M	-24.61M	-24.42M	-25.38M
Net Income Margin	-	-	-273.69%	-109.63%	-326.58%	-287.29%	-4492.42%	-447.26%	-98.20%	-	-	-	-	-	-	-	-	-
R&D	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.50K	8.82M	9.00M	5.12M
Interest Expense	-	61.00K	5.25M	27.87M	24.82M	20.49M	4.09M	1.11M	1.37M	505.00K	125.00K	30.00K	272.00K	665.00K	996.00K	1.56M	4.96M	2.65M
Interest Expense % of Total Revenue	-	-	1016.05%	179.94%	187.30%	41.50%	3101.52%	179.84%	130.08%	-	-	-	-	-	-	-	-	-

Balance Sheet

Currency: DKK	2008-09-30	2009-09-30	2010-09-30	2011-09-30	2012-09-30	2013-09-30	2014-09-30	2015-09-30	2016-09-30	2017-09-30	2018-09-30	2019-09-30	2020-09-30	2021-09-30	2022-09-30	2023-09-30	2024-09-30	2025-09-30
Total Assets	261.67M	75.70M	497.26M	507.76M	503.85M	251.24M	123.97M	126.25M	125.75M	86.30M	80.84M	80.84M	57.58M	63.65M	71.07M	67.74M	65.61M	38.90M
Total Liabilities	205.42M	22.24M	444.20M	428.10M	467.46M	356.68M	26.02M	26.72M	28.98M	1.21M	3.27M	13.68M	23.30M	21.08M	25.03M	42.40M	16.73M	13.43M
Total Equity	56.25M	46.76M	53.06M	79.67M	36.39M	-105.44M	97.69M	94.92M	93.14M	85.09M	77.57M	67.16M	34.28M	42.57M	46.05M	25.33M	48.88M	25.47M
Cash	9.00M	7.70M	3.95M	2.82M	53.52M	20.74M	2.00K	376.00K	1.00K	3.00K	1.00K	1.00K	-	0	182.00K	4.23M	1.54M	498.00K
Total Debt	204.58M	10.06M	241.19M	187.66M	239.73M	322.39M	15.00K	23.21M	7.15M	103.00K	1.49M	1.66M	10.04M	18.93M	22.84M	30.22M	11.04M	8.05M
Net Debt	195.59M	2.36M	237.25M	184.84M	186.21M	301.65M	13.00K	22.83M	7.15M	100.00K	1.49M	1.66M	10.04M	18.93M	22.66M	25.99M	9.50M	7.56M

Cash Flow

Currency: DKK	2008-09-30	2009-09-30	2010-09-30	2011-09-30	2012-09-30	2013-09-30	2014-09-30	2015-09-30	2016-09-30	2017-09-30	2018-09-30	2019-09-30	2020-09-30	2021-09-30	2022-09-30	2023-09-30	2024-09-30	2025-09-30
Operating Cash Flow	-	-744.00K	-17.75M	-5.71M	-10.56M	-5.79M	-4.80M	-2.94M	-181.00K	-4.92M	-1.58M	-274.00K	-9.90M	-2.09M	-2.87M	-16.62M	-22.86M	-17.66M
Investing Cash Flow	-	-13.84M	3.36M	-4.63M	45.81M	25.19M	-	-1.69M	-	-	-	1.65M	-	-	-	-73.00K	-	11.00K
Financing Cash Flow	-	-7.94M	10.64M	9.21M	9.46M	-48.39M	-	5.00M	-751.00K	5.42M	1.58M	-1.38M	9.90M	2.09M	3.06M	17.06M	22.86M	13.91M
Capital Expenditure	0	0	35.17M	4.63M	391.00K	386.00K	0	0	0	0	0	2.05M	0	0	0	73.00K	0	17.66M
Free Cash Flow	-	-744.00K	-52.92M	-10.34M	-10.95M	-6.17M	-4.80M	-2.94M	-181.00K	-4.92M	-1.58M	-2.32M	-9.90M	-2.09M	-2.87M	-16.70M	-22.86M	-17.66M
FCF to OCF	-	100.00%	298.19%	181.01%	103.70%	106.67%	100.00%	100.00%	100.00%	100.00%	100.00%	848.18%	100.00%	100.00%	100.00%	100.44%	100.00%	100.00%

Earnings

Report Date	Mar 31, 2009	Jun 30, 2009	Sep 30, 2009	Dec 31, 2009	Mar 31, 2010	Jun 30, 2010	Sep 30, 2010	Dec 31, 2010	Mar 31, 2011	Jun 30, 2011	Sep 30, 2011	Dec 31, 2011	Mar 31, 2012	Jun 30, 2012	Sep 30, 2012	Dec 31, 2012	Mar 31, 2013	Jun 30, 2013	Sep 30, 2013	Dec 31, 2013	Mar 31, 2014	Jun 30, 2014	Sep 30, 2014	Dec 31, 2014	Mar 31, 2015	Jun 30, 2015	Sep 30, 2015	Mar 31, 2016	May 12, 2016	Aug 25, 2016	Mar 31, 2017	Aug 25, 2017	Apr 6, 2018	Aug 24, 2018	Nov 9, 2018	Mar 29, 2019	May 9, 2019	Aug 23, 2019	Nov 8, 2019	Mar 31, 2020	May 14, 2020	Aug 24, 2020	Nov 6, 2020	Mar 26, 2021	May 13, 2021	Aug 20, 2021	Nov 5, 2021	Apr 1, 2022	Aug 22, 2022	Nov 4, 2022	Mar 31, 2023	May 11, 2023	Aug 16, 2023	Nov 16, 2023	Mar 29, 2024	May 16, 2024	Aug 16, 2024	Nov 15, 2024	Mar 20, 2025
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	0.00	0.00	-0.01	0.00	-0.01	0.00
EPS Actual	-4.22	-3.34	-0.05	-1.82	-0.36	-0.77	-1.04	0.39	-2.24	-2.26	-1.34	-3.38	-1.29	-2.21	-1.92	-13.56	-1.28	-28.04	-2.92	-29.34	-1.45	-0.46	-0.04	-0.03	-0.01	-0.01	-0.02	-0.01	-0.01	-0.01	-0.01	0.00	-0.02	0.01	0.00	-0.07	0.00	-0.03	0.00	-0.11	0.00	-0.77	0.00	-1.58	0.00	-0.04	0.00	0.28	0.08	0.00	0.05	-0.15	-0.00	-0.00	-0.01	-0.01	-0.01	-0.01	-0.02
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00%	-	0.00%	-
Timing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Pre-market	Pre-market	Pre-market

Key Statistics & Ratios

Market Cap98.20M

Enterprise Value100.33M

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.27

Price / Book3.47

EPS-0.01

Book Value0.021

Revenue (TTM)0

Gross Profit (TTM)0

EBITDA-9.88M

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-32.08%

Return on Assets-11.61%

Shares Outstanding1.23B

Shares Float742.25M

Beta1.06

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Jan 27, 20232:1
Oct 29, 20191:10
Feb 24, 201610:1
Dec 27, 20100.3439:1